Quality Of Life While Receiving Faslodex
Quality Of Life And Symptoms In Postmenopausal Women With Hormone Receptor Positive Disseminated Breast Cancer While Receiving Faslodex.
1 other identifier
observational
120
1 country
24
Brief Summary
To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2007
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2007
CompletedFirst Submitted
Initial submission to the registry
March 20, 2008
CompletedFirst Posted
Study publicly available on registry
March 26, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2009
CompletedApril 22, 2009
April 1, 2009
March 20, 2008
April 21, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.
Eligibility Criteria
You may qualify if:
- Histologic and/or cytological proven breast cancer.
- Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months.
- Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor.
- ECOG performance status of ≤ 2
- Patient willingness to take part in the programm
- Life expectancy of more than 6 months.
- Patient ability to complete a questionnaire.
You may not qualify if:
- Contraindications for Faslodex therapy
- Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (24)
Research Site
?rasnodar, Russia
Research Site
Astrakhan, Russia
Research Site
Blagoveshenk, Russia
Research Site
Chita, Russia
Research Site
Igevsk, Russia
Research Site
Kemerovo, Russia
Research Site
Kursk, Russia
Research Site
Magadan, Russia
Research Site
Moscow, Russia
Research Site
Obninsk, Russia
Research Site
Penza, Russia
Research Site
Petropavlovsk, Russia
Research Site
Rostov, Russia
Research Site
Saint Petersburg, Russia
Research Site
Salekhard, Russia
Research Site
Samara, Russia
Research Site
Shahti, Russia
Research Site
Surgut, Russia
Research Site
Tiva, Russia
Research Site
Tomsk, Russia
Research Site
Tver', Russia
Research Site
Ufa, Russia
Research Site
Volgodonsk, Russia
Research Site
Yakutsk, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
March 20, 2008
First Posted
March 26, 2008
Study Start
June 1, 2007
Study Completion
January 1, 2009
Last Updated
April 22, 2009
Record last verified: 2009-04